Tony Mok
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tony Mok has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Yi-Long Wu
Southern Medical University
68 shared publications - Byoung Chul Cho
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
61 shared publications - Shun Lu
Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
54 shared publications - James Chih-Hsin Yang
Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Centre, Taipei, Taiwan
49 shared publications - Sun Min Lim
Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
49 shared publications - Cheng Chen
D3 Bio, Inc., Shanghai, China. 1
48 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Data from First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non–Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study
Purpose:EVOKE-02 (NCT05186974) is a multicohort, phase II trial evaluating first-line sacituzumab govitecan (SG) plus pembrolizumab with or without platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (mNSCLC).Patients and Methods:Adults with mNSCLC, no prior systemic treatment, and no actionable genomic alterations received SG 10 mg/kg intravenously (reduced to 7.5 mg/kg following a preplanned safety evaluation) on days 1 and 8, plus pembrolizumab 200 mg intravenously on day 1 and carboplatin area under the curve 5 on day 1 in 21-day cycles. The primary endpoint was objective response rate (ORR) per independent review committee; secondary endpoints included progression-free survival (PFS) and safety.Results:As of June 3, 2024, 54 and 41 patients had nonsquamous and squamous histology, respectively. ORR (95% confidence interval [CI]) was 45.1% (3.1–59.7) for nonsquamous and 39.0% (24.2–55.5) for squamous histology. Median (95% CI) PFS was 8.1 (5.2–15.0) months for nonsquamous and 8.3 (4.3–11.2) months for squamous histology. ORR (95% CI) was 66.7% (34.9–90.1) for programmed cell death-ligand 1 tumor proportion score greater than or equal to 50%. SG dose was adjusted to 7.5 mg/kg due to myelosuppression. Grade greater than or equal to 3 treatment-emergent adverse events (TEAEs) occurred in 57 patients (86.4%). TEAEs leading to discontinuation of any study drug occurred in 12 patients (18.2%).Conclusions:SG plus pembrolizumab and carboplatin had activity in mNSCLC. When combined with pembrolizumab and carboplatin, SG was tolerated at a dose of 7.5 mg/kg.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non–Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study
Purpose:EVOKE-02 (NCT05186974) is a multicohort, phase II trial evaluating first-line sacituzumab govitecan (SG) plus pembrolizumab with or without platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (mNSCLC).Patients and Methods:Adults with mNSCLC, no prior systemic treatment, and no actionable genomic alterations received SG 10 mg/kg intravenously (reduced to 7.5 mg/kg following a preplanned safety evaluation) on days 1 and 8, plus pembrolizumab 200 mg intravenously on day 1 and carboplatin area under the curve 5 on day 1 in 21-day cycles. The primary endpoint was objective response rate (ORR) per independent review committee; secondary endpoints included progression-free survival (PFS) and safety.Results:As of June 3, 2024, 54 and 41 patients had nonsquamous and squamous histology, respectively. ORR (95% confidence interval [CI]) was 45.1% (3.1–59.7) for nonsquamous and 39.0% (24.2–55.5) for squamous histology. Median (95% CI) PFS was 8.1 (5.2–15.0) months for nonsquamous and 8.3 (4.3–11.2) months for squamous histology. ORR (95% CI) was 66.7% (34.9–90.1) for programmed cell death-ligand 1 tumor proportion score greater than or equal to 50%. SG dose was adjusted to 7.5 mg/kg due to myelosuppression. Grade greater than or equal to 3 treatment-emergent adverse events (TEAEs) occurred in 57 patients (86.4%). TEAEs leading to discontinuation of any study drug occurred in 12 patients (18.2%).Conclusions:SG plus pembrolizumab and carboplatin had activity in mNSCLC. When combined with pembrolizumab and carboplatin, SG was tolerated at a dose of 7.5 mg/kg.
- Retraction
- 24 June 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (7) , 2691
Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial
- 24 June 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (7) , 2691
RetractionRetraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S4 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Supplemental Table S4 summarizing RNAseq and WES analysis of acquired resistant clones from MIA PaCa-2 xenograft model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S4 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Supplemental Table S4 summarizing RNAseq and WES analysis of acquired resistant clones from MIA PaCa-2 xenograft model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental material and methods from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Addition information for material and methods
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental material and methods from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Addition information for material and methods
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S8 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Supplemental Figure S8 shows brain penetration profile of adagrasib in beagle dogs and SD rats
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S8 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Supplemental Figure S8 shows brain penetration profile of adagrasib in beagle dogs and SD rats
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S4 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Supplemental Figure S4 shows dose-dependent curves for each cell line.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S4 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Supplemental Figure S4 shows dose-dependent curves for each cell line.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Supplemental Table S1 summarizing the anti-proliferative potency of D3S-001, adagrasib and sotorasib.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Supplemental Table S1 summarizing the anti-proliferative potency of D3S-001, adagrasib and sotorasib.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S6 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Supplemental Figure S6 shows baseline mutation landscape of the 10 colorectal cancer PDX models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S6 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Supplemental Figure S6 shows baseline mutation landscape of the 10 colorectal cancer PDX models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Supplemental Figure S2 shows the percentage of KRAS G12C target engagement determined by different methods.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Supplemental Figure S2 shows the percentage of KRAS G12C target engagement determined by different methods.